Anaplastic Thyroid Cancer Clinical Trials 2024

What are the top hospitals conducting anaplastic thyroid cancer research?

In the world of anaplastic thyroid cancer, a rare and aggressive form of the disease, several hospitals are leading the charge in clinical trials. Among them is Houston's M D Anderson Cancer Center, which currently has four active trials dedicated to this challenging condition. Since conducting their first trial in 2010, they have played a crucial role in advancing our understanding and treatment options for anaplastic thyroid cancer. Meanwhile, Memorial Sloan Kettering (MSK) is making significant contributions through its various locations specializing in limited protocol activities.

At MSK Basking Ridge in Basking Ridge, there are two ongoing anaplastic thyroid cancer trials alongside their two previously conducted studies initiated as recently as 2017. Similarly, MSK Monmouth in Middletown and MSK Bergen in Montvale each have two active clinical trials specific to this type of cancer with identical numbers of previous investigations.

It is worth noting that these facilities under the renowned umbrella of Memorial Sloan Kettering Cancer Center strive relentlessly to improve outcomes for patients facing anaplastic thyroid cancer by exploring novel approaches and treatments through clinical research conducted at these regional centers like Commack location where they boast another pair of ongoing trials just within years' time from beginning their discovery path towards combating this uncommon condition back then during 2017.

Though it may seem that progress is gradual due to limited numbers compared to other cancers or medical conditions; however every step taken towards better understanding and management brings us closer to breakthroughs that offer hope for those affected by anaplastic thyroid cancer—an encouraging prospect amidst such adversity.

Which are the best cities for anaplastic thyroid cancer clinical trials?

When it comes to anaplastic thyroid cancer clinical trials, several cities are leading the way in research and development. Houston, Texas; Basking Ridge and Middletown in New jersey; as well as Harrison, New york have all shown significant activity with four active trials each. These trials investigate promising treatments like Pembrolizumab, Vudalimab, Autologous Tumor Infiltrating Lymphocytes LN-145, Dabrafenib, Trametinib, among others. Additionally, Ann Arbor in Michigan has two active trials studying Pembrolizumab and MLN0128. With their dedication to advancing treatment options for anaplastic thyroid cancer patients through rigorous clinical research studies, these cities provide valuable opportunities for individuals seeking innovative approaches to combat this challenging disease.

Which are the top treatments for anaplastic thyroid cancer being explored in clinical trials?

Anaplastic thyroid cancer is a challenging disease that requires innovative treatment approaches. In the realm of clinical trials, several top treatments are being explored to combat this aggressive form of cancer:

• Pembrolizumab: Currently under investigation in two active anaplastic thyroid cancer trials. It has shown promise since its introduction in 2016, with five all-time trials dedicated to this specific type of cancer.

• Vudalimab: A newcomer on the scene, vudalimab is currently being tested in one active trial for anaplastic thyroid cancer. First listed in 2022, it holds potential as a novel treatment option.

• Dabrafenib: This targeted therapy shows promise and is currently involved in one ongoing anaplastic thyroid cancer trial. Since its first listing in 2020, dabrafenib has been evaluated across four all-time clinical trials for this particular disease.

• Intensity-Modulated Radiation Therapy (IMRT): Recognized as a valuable approach for anaplastic thyroid cancer management, IMRT is currently investigated through one active trial. Its effectiveness has been studied extensively since it was initially listed as a treatment method back in 2010.

• Autologous Tumor Infiltrating Lymphocytes LN-145: Another emerging avenue of research lies within autologous tumor infiltrating lymphocytes LN-145 therapy. With one active trial underway and first introduced as a potential treatment option for anaplastic thyroid cancer patients in 2018.

These treatments offer hope and highlight the dedication researchers have towards finding effective solutions against anaplastic thyroid cancer.

What are the most recent clinical trials for anaplastic thyroid cancer?

Recent clinical trials offer hope in the field of anaplastic thyroid cancer research. Vudalimab and pembrolizumab have shown promise in Phase 2 trials, with vudalimab becoming available on 7/21/2022, and pembrolizumab on 11/21/2021 and 6/24/2021 respectively. These immunotherapy treatments hold potential for improving patient outcomes. Additionally, intensity-modulated radiation therapy is being explored as a treatment option for anaplastic thyroid cancer through a Phase 1 trial that became available on 9/14/2020. Furthermore, dabrafenib has displayed encouraging results in Phase 2 trials since its availability on 1 /20 /2020. These recent advancements bring new possibilities to individuals fighting against anaplastic thyroid cancer.

What anaplastic thyroid cancer clinical trials were recently completed?

A recent clinical trial for anaplastic thyroid cancer investigated the effectiveness of durvalumab, a promising treatment option. Sponsored by Memorial Sloan Kettering Cancer Center, this trial was successfully completed in April 2017. The completion of this study provides valuable insights into the potential benefits and limitations of durvalumab as a therapeutic approach for patients with anaplastic thyroid cancer.